At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Pre-Mkt 09-18 06:33:49 EDT
534.40
+5.31
+1.00%
High539.29Low526.26Vol153.31K
Open534.69D1 Closing529.09Amplitude2.46%
Mkt Cap12.32BTradable Cap7.33BTotal Shares23.06M
T/O81.58MT/O Rate1.12%Tradable Shares13.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Madrigal Grants Inducement Equity Awards to 27 New Hires, Including 2,754 Stock Options Priced at USD 538.71
Reuters  ·  09-17 04:05
Madrigal Grants Inducement Equity Awards to 27 New Hires, Including 2,754 Stock Options Priced at USD 538.71
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-17 04:05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  09-17 04:05
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharma CEO William John Sibold Disposes of Common Shares Worth $4.16 Million
Reuters  ·  09-12
Madrigal Pharma CEO William John Sibold Disposes of Common Shares Worth $4.16 Million
Madrigal Pharmaceuticals to Present at Cantor Global Healthcare Conference
Reuters  ·  09-02
Madrigal Pharmaceuticals to Present at Cantor Global Healthcare Conference
Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?
Simply Wall St.  ·  08-29
Can Madrigal Pharmaceuticals (MDGL) Still Offer Value After Its Big Run?
Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92
Market Focus  ·  08-27
Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92
Madrigal Grants 4,676 Inducement RSUs to 13 New Employees Under 2025 Plan
Reuters  ·  08-21
Madrigal Grants 4,676 Inducement RSUs to 13 New Employees Under 2025 Plan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  08-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards Under NASDAQ Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-21
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Simply Wall St.  ·  08-20
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow
Madrigal Pharma Director John C. Reed Files Initial Beneficial Ownership Statement
Reuters  ·  08-19
Madrigal Pharma Director John C. Reed Files Initial Beneficial Ownership Statement
Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
TIPRANKS  ·  08-14
Madrigal Extends Resmetirom Into Pediatric MASH, Boosting Long-Term Upside for MDGL
Madrigal Pharmaceuticals Adds Renowned Leader to Board
TIPRANKS  ·  08-12
Madrigal Pharmaceuticals Adds Renowned Leader to Board
Madrigal Appoints J&J R&D Chief John Reed to Board
Reuters  ·  08-12
Madrigal Appoints J&J R&D Chief John Reed to Board
Madrigal Appoints John C. Reed, M.d., Ph.d., to Its Board of Directors
THOMSON REUTERS  ·  08-12
Madrigal Appoints John C. Reed, M.d., Ph.d., to Its Board of Directors
Press Release: Madrigal Appoints John C. Reed, M.D., Ph.D., to Its Board of Directors
Dow Jones  ·  08-12
Press Release: Madrigal Appoints John C. Reed, M.D., Ph.D., to Its Board of Directors
Madrigal Pharmaceuticals Grants 4,263 Inducement RSUs to 10 New Employees
Reuters  ·  08-07
Madrigal Pharmaceuticals Grants 4,263 Inducement RSUs to 10 New Employees
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-07
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Present at Canaccord Genuity Annual Growth Conference
Reuters  ·  08-06
Madrigal Pharmaceuticals to Present at Canaccord Genuity Annual Growth Conference

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--